New FDA Warning Added to Popular Weight Loss Drugs
Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration during general anesthesia or deep sedation. The affected drugs are liraglutide (Saxenda, Victoza), semaglutide (Ozempic, Rybelsus, Wegovy), and tirzepatide (Mounjaro, Zepbound).
Medicaid covers GLP-1 weight-loss drugs in just 13 states
Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.
Map Shows States Where Weight Loss Drugs are Most Popular
Kentucky, Alaska and Alabama are the three states where weight loss drugs are most used, and Hawaii, Arizona and Colorado sit at the other end of the spectrum, a report has revealed. Glucagon-like peptide-1 (GLP-1) receptor analogs are drugs that mimic fullness hormone GLP-1 and have been shown to reduce appetite,
Medicaid Covers GLP-1 Meds for Obesity in Just 13 States
Expanding Medicaid coverage of these drugs could increase access for the almost 40% of adults and 26% of children with obesity in Medicaid,” wrote the research team led by se
Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs
These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates appetite and digestion. The medications control blood sugar and help people eat less,
States slow to cover GLP-1s for weight loss
Axios Visuals Budget pressures have kept all but 13 states from covering GLP-1 drugs for weight loss through their Medicaid programs, a new report from KFF shows. Why it matters: The restrictive policies add to equity concerns around the blockbuster drugs,
Medscape1d
FDA Updates GLP-1 Label with Pulmonary Aspiration Warning
On November 5, the US Food and Drug Administration (FDA) updated the labels for all glucagon-like peptide 1 receptor agonists (GLP-1 RA) with a warning about pulmonary aspiration during general ...
Today's Dietitian magazine9h
Do Certain Diabetes Drugs Increase the Risk of Acute Kidney Injury in Patients Taking Anti-Cancer Therapies?
News Do Certain Diabetes Drugs Increase the Risk of Acute Kidney Injury in Patients Taking Anti-Cancer Therapies? Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medicatio ...
Improvement seen in some features of PCOS with weight loss interventions
Weight loss interventions are associated with improvement in some features of polycystic ovary syndrome (PCOS), according to ...
Verywell Health on MSN9h
Does Ozempic Impact Kidney Health?
Medically reviewed by Lindsay Cook, PharmD Ozempic is the brand name of semaglutide, a glucagon-like peptide-1 (GLP-1) ...
Managed Healthcare Executive10h
GLP-1 Benefits For People With Ulcerative Colitis and Obesity
Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...
Guidance issued for safe use of GLP-1 RAs in the perioperative period
In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...
Too Old to Operate8d
Glucagon-like peptide-1 receptor agonists may impact outcomes of endoscopy
The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not ...
Medscape1d
Knowledge Gaps About Obesity Medicine Seen in Primary Care
especially for non–glucagon-like peptide 1 (GLP-1) receptor agonists. One third reported that they didn’t prescribe AOMs, ...
NBC Los Angeles1d
Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance
Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...
GlobalData on MSN1d
Viking stock fluctuates amid manufacturing concerns with obesity pill
Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.